Relief Cardiovascular has announced positive 90-day results from a study of its smart heart implant technology.
Physician-scientists announced today the results of the largest cell therapy trial to date in patients with chronic heart failure due to low ejection fraction. The therapy benefited patients by ...
Morning Overview on MSN
CRISPR approach targets mitochondria to aid heart failure treatment
Rice University researchers have developed a CRISPR-based gene activation strategy that boosts mitochondrial production in damaged heart cells, improving cardiac function after heart attacks in both ...
Relief Cardiovascular, Inc., a private medical device company developing intelligent device-based therapy solutions for heart failure (HF) congestion, today announced positive 90-day results from the ...
—Starting cardiac medications, using the proper timing and dosing, to optimize the efficacy of therapies and improve patient outcomes, is key to cardiac care for patients with Duchenne muscular ...
Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial We evaluated 2,808 echocardiograms in 829 breast cancer ...
Oxygen saturation at 6 minutes improved with oxygen use, but perceived exertion scores (Borg dyspnea index) did not change.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results